home / stock / apre / apre quote
Last: | $ |
---|---|
Change Percent: | -0.29% |
Open: | $34.88 |
Close: | $34.52 |
High: | $36.00 |
Low: | $34.11 |
Volume: | 25,629 |
Last Trade Date Time: | 02/12/2020 04:44:03 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $34.88 | $34.52 | $36.00 | $34.11 | 25,629 | 02-12-2020 |
$ | $34.96 | $34.62 | $36.895 | $34.41 | 41,841 | 02-11-2020 |
$ | $35.35 | $34.80 | $36.25 | $34.06 | 46,652 | 02-10-2020 |
$ | $36.31 | $35.11 | $37.42 | $34.04 | 61,776 | 02-07-2020 |
$ | $38.15 | $36.02 | $38.37 | $35.01 | 56,377 | 02-06-2020 |
$ | $39.37 | $37.96 | $39.37 | $37.185 | 42,989 | 02-05-2020 |
$ | $39.63 | $38.48 | $39.7855 | $37.12 | 67,950 | 02-04-2020 |
$ | $39.27 | $39.50 | $39.93 | $37.48 | 73,734 | 02-03-2020 |
$ | $37.42 | $38.34 | $38.73 | $36.60 | 65,042 | 01-31-2020 |
$ | $38.97 | $37.23 | $38.97 | $36.2884 | 73,125 | 01-30-2020 |
$ | $35.76 | $35.85 | $36.8148 | $34.00 | 90,899 | 01-29-2020 |
$ | $38.12 | $35.94 | $38.97 | $35.31 | 122,631 | 01-28-2020 |
$ | $37.95 | $37.84 | $38.78 | $36.18 | 102,327 | 01-27-2020 |
$ | $40.51 | $38.58 | $40.74 | $38.40 | 83,992 | 01-24-2020 |
$ | $39.87 | $40.34 | $40.6645 | $38.48 | 62,502 | 01-23-2020 |
$ | $39.68 | $40.00 | $40.25 | $38.45 | 118,744 | 01-22-2020 |
$ | $39.45 | $38.83 | $39.94 | $38.49 | 68,442 | 01-21-2020 |
$ | $42.18 | $39.48 | $42.7725 | $39.03 | 61,389 | 01-20-2020 |
$ | $42.18 | $39.48 | $42.7725 | $39.03 | 61,387 | 01-17-2020 |
$ | $40.53 | $42.46 | $43.24 | $38.365 | 106,992 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Aprea Therapeutics Inc. Company Name:
APRE Stock Symbol:
NYSE Market:
2024-05-16 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051 clinical trial in June 2024 First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation in ABOYA-119 c...
DOYLESTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical stage biopharmac...